185 related articles for article (PubMed ID: 24833327)
21. N-acetylcysteine reduces the exacerbation rate in patients with moderate to severe COPD.
Pela R; Calcagni AM; Subiaco S; Isidori P; Tubaldi A; Sanguinetti CM
Respiration; 1999; 66(6):495-500. PubMed ID: 10575333
[TBL] [Abstract][Full Text] [Related]
22. Fluticasone and N-acetylcysteine in primary care patients with COPD or chronic bronchitis.
Schermer T; Chavannes N; Dekhuijzen R; Wouters E; Muris J; Akkermans R; van Schayck O; van Weel C
Respir Med; 2009 Apr; 103(4):542-51. PubMed ID: 19138505
[TBL] [Abstract][Full Text] [Related]
23. LANTERN: a randomized study of QVA149 versus salmeterol/fluticasone combination in patients with COPD.
Zhong N; Wang C; Zhou X; Zhang N; Humphries M; Wang L; Thach C; Patalano F; Banerji D;
Int J Chron Obstruct Pulmon Dis; 2015; 10():1015-26. PubMed ID: 26082625
[TBL] [Abstract][Full Text] [Related]
24. Effect of high-dose N-acetylcysteine on airway geometry, inflammation, and oxidative stress in COPD patients.
De Backer J; Vos W; Van Holsbeke C; Vinchurkar S; Claes R; Parizel PM; De Backer W
Int J Chron Obstruct Pulmon Dis; 2013; 8():569-79. PubMed ID: 24293993
[TBL] [Abstract][Full Text] [Related]
25. The efficacy and safety of combination salmeterol (50 microg)/fluticasone propionate (500 microg) inhalation twice daily via accuhaler in Chinese patients with COPD.
Zheng JP; Yang L; Wu YM; Chen P; Wen ZG; Huang WJ; Shi Y; Wang CZ; Huang SG; Sun TY; Wang GF; Xiong SD; Zhong NS
Chest; 2007 Dec; 132(6):1756-63. PubMed ID: 17951625
[TBL] [Abstract][Full Text] [Related]
26. Monotherapy with indacaterol once daily reduces the rate of exacerbations in patients with moderate-to-severe COPD: Post-hoc pooled analysis of 6 months data from three large phase III trials.
Wedzicha JA; Buhl R; Lawrence D; Young D
Respir Med; 2015 Jan; 109(1):105-11. PubMed ID: 25433954
[TBL] [Abstract][Full Text] [Related]
27. Effect of budesonide/formoterol pMDI on COPD exacerbations: a double-blind, randomized study.
Sharafkhaneh A; Southard JG; Goldman M; Uryniak T; Martin UJ
Respir Med; 2012 Feb; 106(2):257-68. PubMed ID: 22033040
[TBL] [Abstract][Full Text] [Related]
28. Inflammatory biomarkers and exacerbations in chronic obstructive pulmonary disease.
Thomsen M; Ingebrigtsen TS; Marott JL; Dahl M; Lange P; Vestbo J; Nordestgaard BG
JAMA; 2013 Jun; 309(22):2353-61. PubMed ID: 23757083
[TBL] [Abstract][Full Text] [Related]
29. Effect of once-daily fluticasone furoate/vilanterol on 24-hour pulmonary function in patients with chronic obstructive pulmonary disease: a randomized, three-way, incomplete block, crossover study.
Boscia JA; Pudi KK; Zvarich MT; Sanford L; Siederer SK; Crim C
Clin Ther; 2012 Aug; 34(8):1655-66.e5. PubMed ID: 22789766
[TBL] [Abstract][Full Text] [Related]
30. Withdrawal of inhaled corticosteroids in people with COPD in primary care: a randomised controlled trial.
Choudhury AB; Dawson CM; Kilvington HE; Eldridge S; James WY; Wedzicha JA; Feder GS; Griffiths CJ
Respir Res; 2007 Dec; 8(1):93. PubMed ID: 18162137
[TBL] [Abstract][Full Text] [Related]
31. The Bronchitis Randomized On NAC Cost-Utility Study (BRONCUS): hypothesis and design. BRONCUS-trial Committee.
Decramer M; Dekhuijzen PN; Troosters T; van Herwaarden C; Rutten-van Mölken M; van Schayck CP; Olivieri D; Lankhorst I; Ardia A
Eur Respir J; 2001 Mar; 17(3):329-36. PubMed ID: 11405507
[TBL] [Abstract][Full Text] [Related]
32. Effect of ADRB2 polymorphisms on the efficacy of salmeterol and tiotropium in preventing COPD exacerbations: a prespecified substudy of the POET-COPD trial.
Rabe KF; Fabbri LM; Israel E; Kögler H; Riemann K; Schmidt H; Glaab T; Vogelmeier CF
Lancet Respir Med; 2014 Jan; 2(1):44-53. PubMed ID: 24461901
[TBL] [Abstract][Full Text] [Related]
33. Effect of 1-year treatment with roflumilast in severe chronic obstructive pulmonary disease.
Calverley PM; Sanchez-Toril F; McIvor A; Teichmann P; Bredenbroeker D; Fabbri LM
Am J Respir Crit Care Med; 2007 Jul; 176(2):154-61. PubMed ID: 17463412
[TBL] [Abstract][Full Text] [Related]
34. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial.
Cosío BG; Shafiek H; Iglesias A; Yanez A; Córdova R; Palou A; Rodriguez-Roisin R; Peces-Barba G; Pascual S; Gea J; Sibila O; Barnes PJ; Agusti A
Chest; 2016 Jul; 150(1):123-30. PubMed ID: 27107490
[TBL] [Abstract][Full Text] [Related]
35. N-Acetylcysteine protects human bronchi by modulating the release of neurokinin A in an ex vivo model of COPD exacerbation.
Calzetta L; Rogliani P; Facciolo F; Rinaldi B; Cazzola M; Matera MG
Biomed Pharmacother; 2018 Jul; 103():1-8. PubMed ID: 29635121
[TBL] [Abstract][Full Text] [Related]
36. 'Exacerbation-free time' to assess the impact of exacerbations in patients with chronic obstructive pulmonary disease (COPD): a prospective observational study.
Boer LM; Bischoff EW; Borgijink X; Vercoulen JH; Akkermans RP; Kerstjens HAM; Assendelft WJ; Schermer TR
NPJ Prim Care Respir Med; 2018 Apr; 28(1):12. PubMed ID: 29615628
[TBL] [Abstract][Full Text] [Related]
37. A post hoc pooled analysis of exacerbations among US participants in randomized controlled trials of tiotropium.
Anzueto A; Niewoehner DE; Leimer I; Rühmkorf F; Celli BR; Decramer M; Tashkin DP
Respir Med; 2013 Dec; 107(12):1912-22. PubMed ID: 23969305
[TBL] [Abstract][Full Text] [Related]
38. Pharmacological investigation on the anti-oxidant and anti-inflammatory activity of N-acetylcysteine in an ex vivo model of COPD exacerbation.
Cazzola M; Calzetta L; Facciolo F; Rogliani P; Matera MG
Respir Res; 2017 Jan; 18(1):26. PubMed ID: 28118826
[TBL] [Abstract][Full Text] [Related]
39. Increased hydrogen peroxide concentration in the exhaled breath condensate of stable COPD patients after nebulized N-acetylcysteine.
Rysz J; Stolarek RA; Luczynski R; Sarniak A; Wlodarczyk A; Kasielski M; Nowak D
Pulm Pharmacol Ther; 2007; 20(3):281-9. PubMed ID: 16753318
[TBL] [Abstract][Full Text] [Related]
40. Comparison of the efficacy and safety of arformoterol 15 microg twice daily and arformoterol 30 microg once daily in COPD: a single-dose, multicenter, randomized, modified-blind, two-way crossover study.
Panettieri RA; MacIntyre N; Sims M; Kerwin E; Fogarty C; Noonan M; Claus R; Andrews WT
Clin Ther; 2009 Aug; 31(8):1716-23. PubMed ID: 19808130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]